|
| Trial |
Treatment administration |
Main evaluation end-points |
| Drugs |
Dose regimen |
Duration |
| 1 |
Allopurinol vs placebo |
300mg/d (creatinine<150mmol/L)
100mg/d(creatinine>150mmol/L) |
2 months |
Heart rate variability(HRV), arrhythmia |
| 2 |
Allopurinol |
0.5, 1.0, 1.5ug/min
each for 15 minutes* |
45 minutes |
Left ventricular efficiency, hemodynamic measurements |
| 3 |
Allopurinol vs placebo |
300mg/d |
1 month |
Endothelial function,oxidase stress, hemodynamic measurements |
| 4 |
Allopurinol vs placebo |
600ug/min** |
- |
Endothelial function, biochemical parameters |
| 5 |
Allopurinol vs placebo |
300mg/d |
≥7 days |
Endothelial function,oxidase stress, biochemical parameters |
| 6 |
Allopurinol vs placebo |
300mg/d |
3 months |
BNP, exercise capacity, biochemical parameters |
| 7 |
Allopurinol vs placebo |
300mg/d 600mg/d |
1 month |
Endothelial function, BNP, biochemical parameters |
| 8 |
oxypurinolvs glucose |
400mg** |
15 minutes |
Left ventricular function, biochemical parameters |
| 9 |
Allopurinol vsrosuvastatin |
Allo: 300mg/d Rosu: 10mg/d |
1 month |
Heart remodeling, NT-pro BNP |
| 10 |
Allopurinol + atorvastatin vs placebo + atorvastatin |
Allo: 300mg/dAtor: 20mg/d |
4 weeks |
Endothelial function, oxidase stress, heart remodeling, exercise capacity |
| 11 |
Allopurinol |
300mg/d |
36 weeks |
Left myocardial function, biochemical parameters |
| 12 |
Allopurinol |
- |
- |
Endothelial function, oxidase stress, hemodynamic measurements |
| 13 |
Allopurinol vsrosuvastatinvs placebo |
Allo: 300mg/d Rosu: 10 mg/d |
1 month |
Endothelial function, myeloperoxidase(MPO), NT-pro BNP, biochemical parameters |
| 14 |
Allopurinol |
300mg/d(only for the elevated UA) |
3 months |
Left ventricular function, coronary microvascular function |
| 15 |
Allopurinol vs placebo |
300mg** |
- |
Myocardial energy metabolism, hemodynamic measurements |
| 16 |
Allopurinol vs prednisone |
Allo: 300mg/d Pred: 1mg/kg/d |
4 weeks |
NT-proBNP, NYHA functional class, biochemical parameters |
| 17 |
Allopurinol vs placebo |
600mg/d |
9 months |
Left ventricular mass,endothelial function |
| 18 |
Allopurinol vs placebo |
600mg/d |
6 weeks |
BNP,exercise capacity, biochemical parameters |
| 19 |
Allopurinol vs placebo |
300mg/d 4W + 600mg/d 4W |
8 weeks |
Endothelial function, oxidase stress, BNP, biochemical parameters |
*Allopurinol was administered directly into the left coronary artery.
**Allopurinolwas administered through intravenous injection- No related information was provided.
BNP: B-type natriuretic peptide; NT-proBNP: N-terminal pro-brain natriuretic peptide |
